domino pizza inc hold pt see acceler share gain amid peer woe believ stock price
upsid limit maintain hold rais pt analyst stephen anderson full summari
neurotrop inc ntrp buy pt bryostatin phase confirmatori trial alzheim diseas underway
veru inc veru buy pt xtandi move nmcrpc expand opportun
corpor event call maxim salesperson inform
neurotrop bioscienc ntrp cover palomequ ndr ny ceo charl ryan thur juli
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
alarm com hold inc ndr milwauke cfo steve valenzuela wed aug
agilysi inc cover klee ndr nyc ceo ramesh srinivasan cfo toni pritchett thur sept
agilysi inc cover klee ndr boston ceo ramesh srinivasan cfo toni pritchett fri sept
profir energi inc pfie cover jang ndr boston ceo brenton hatch cfo ryan oviatt tue juli
msc industri direct co inc group dinner nyc ceo erik gershwind mon aug
see acceler share gain amid peer woe
believ stock price upsid limit maintain hold rais
pt
maintain hold rate though rais price
target ahead compani releas june
earn juli
although maintain in-lin ep estim rais
ep estim vs consensu ep
estim vs consensu amid fresh concern
peer papa john pzzanr likelihood acceler market share
gain next quarter
dpz posit fundament warrant premium multipl view
believ posit price share
anticip relinquish addit market share follow last week
departur founder chairman john schnatter week dpz earn
report first one overseen ritch allison took ceo
retir patrick doyl juli opinion time could
better particularli mr schnatter step ceo januari
controversi comment attribut declin sale nation footbal
leagu nfl also resign chairman post last week amid new alleg
derogatori comment made confer call may follow
resign sever major leagu basebal mlb team also sever tie
argu loss key part pzza market strategi notabl use mr
schnatter chief spokesperson compani tie major leagu sport
threaten depress sale least next sever quarter
although pizza hut own yumnr sign agreement
becom offici pizza nfl believ stand gain
pizza hut pzza woe given dpz statu tech-savvi conveni
brand well valu reput demonstr nine-year-old campaign
two medium pizza increas comp forecast see page
result market share gain much next two
three quarter add ep forecast annual
basi moreov believ ancillari effect increas sale store-level
effici gain acceler store growth vi -- vi peer could add least anoth
annual ep much upsid built model
nevertheless still believ dpz strong fundament result
premium multipl alreadi price share thu
recommend wait attract re-entri point dpz forward price-to-earnings multipl
well closest peer forward price-to-earnings multipl
base consensu ep estim acknowledg wide gap
valuat multipl reflect manag abil execut well increas
multipl target slightli reflect renew concern howev
contend near peak cyclic valuat multipl forward
price-to-earnings forward ev/ebitda potenti upsid top-lin growth
balanc potenti bottom-lin risk notabl higher labor cost
potenti increas interest cost equal weight forward price-to-earnings multipl
base multipl target forward ev/ebitda multipl base multipl
target sum-of-part methodolog use base valuat year
arriv new price target
click full note
bryostatin phase confirmatori trial alzheim
neurotrop announc first patient enrol
confirmatori phase trial moder sever alzheim
patient recruit take place approxim clinic site
unit state enrol expect complet
primari efficaci endpoint chang sever impair batteri sib
score baselin averag week data expect
trial aim confirm dose refin patient select valid result
seen trial remind prior studi patient
concurr receiv memantin experienc improv cognit
impair appear continu treatment stop data
suggest therapeut signal support bryostatin moa
may includ regener synaps popul subject
on-going studi
conclus initi studi posit compani view
step back evalu prior data data present
aaic next week design enrich confirmatori studi
better defin dose patient popul smart approach
pave way
activ alzheim diseas space aaic alzheim associ
announc data antibodi target amyloid beta
demonstr improv adcom month data top-lin
expect detail data would indic path forward
aaic given sharp rise share news expect addit data
could impact well other space includ neurotrop
specif target reduct bryostatin differ class drug
differ mechan action target pkc target pkc induc multipl
effect ad pathogenesi import may revers cognit
declin via synaps regener synaps loss directli correl cognit loss
direct correl tau phosphoryl less clear bryostatin
addit potenti synaps regener also contribut elimin
oligom amyloid plaqu via activ degrad enzym brain
view alzheim diseas histor difficult indic drug
develop due multipl factor includ larg patient popul diseas
heterogen promis data continu emerg includ neurotrop
multi-mod activ view still earli stage long clinic
path ahead bryostatin could potenti success approach
phase trial design trial enrol ad patient moder sever
ad defin mental state exam primari efficaci
endpoint chang sever impair batteri sib score baselin
averag week patient random
vs placebo dose week patient memantin nmda receptor
antagonist exclud unless memantin day
memantin bryostatin target nmda receptor prior studi
differenti efficaci observ on-memantin effect off-memantin
therapeut effect may due engag receptor
bryostatin memantin present
click full note
xtandi move nmcrpc expand opportun
last friday pfizer xtandi enzaluatamid approv non-metastat
castrat resist prostat cancer nmcrpc signific news pc
space view posit veru
paradigm shift prostat cancer pc treatment
prior high patient asymptomat treat cancer
eventu break castrat resist progress first
metastasi treat anti-androgen xtandi zytiga cancer
break iv anti-tubulin chemo next
high come first xtandi erleada approv
feb given high still asymptomat diseas
metastasi overal much larger popul move
therapeut pyramid shift standard care
translat anti-androgen use earlier even though
time diseas progress extend resist cancer
breakthrough still like occur challeng xtandi erleada
zytiga use interchang sequenti due cross-
read-through veru anti-androgen pre-metastasi
set first met patient experi exhaust
anti-androgen option earlier diseas
significantli larger opportun potenti bridg
anti-androgen iv chemotherapi forget
patient live longer therapi hot flash
larger opportun well
oral chemotherapi could serv bridg
anti-androgen therapi resist seen year taxan iv
chemotherapi veru initi evalu treatment mcrpc
expect initi approv xtandi nmcrpc
follow approv erleada signal us incorpor anti-
androgen treatment paradigm expand larger pc popul earlier
diseas shift soc default increas opportun
potenti bridg therapi iv chemotherapi present
move trial patient fail anti-androgen data expect
primari endpoint reduct prostate-specif antigen expect
signific reduct popul attract attent
space
veru investig repurpos clomid cis-clomiphen
treatment hot flash result use wide treat men advanc
prostat cancer noth present approv side effect erleada
xtandi approv nmcprc demonstr clinic studi rate
hot flash higher studi demonstr hot flash rate combin
vs alon veru studi evalu dose
vs placebo initi data primari endpoint chang
frequenc moder sever hot flash baselin week
endpoint led approv hot-flash-rel therapi postmenopaus
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
